CCRA Investigational Product Management 2 — Questions and Answers
Question 1: Good Manufacturing Practice (GMP) requirements for investigational products are primarily intended to ensure:
- Cost-effective production of clinical supplies
- Product quality, identity, purity, and potency for subject safety and reliable trial results (Correct answer)
- Rapid manufacturing to meet enrollment timelines
- Compatibility with commercial packaging standards
Correct answer: Product quality, identity, purity, and potency for subject safety and reliable trial results
GMP for investigational products (21 CFR Part 211 in the US) ensures that manufacturing processes produce consistent, safe, and accurately labeled product that supports both subject safety and data integrity.
Question 2: What information must appear on investigational product labels per GCP and regulatory requirements?
- Only the product name and lot number
- Trial number, protocol ID, subject/dose information, storage conditions, sponsor contact, and the statement 'For Clinical Trial Use Only' (Correct answer)
- Commercial product name and manufacturer address
- Subject name, date of birth, and insurance information
Correct answer: Trial number, protocol ID, subject/dose information, storage conditions, sponsor contact, and the statement 'For Clinical Trial Use Only'
GCP IP labels must include the clinical trial identification, dosing information, storage requirements, sponsor or manufacturer contact, and the mandatory statement that the product is for investigational use only.
Question 3: Subject medication compliance (adherence) is most commonly assessed in clinical trials by:
- Sponsor review of financial payment records
- Pill/device counts, subject diaries, or plasma drug level measurements (Correct answer)
- Investigator opinion during clinic visits
- Subject self-report at final visit only
Correct answer: Pill/device counts, subject diaries, or plasma drug level measurements
Compliance is typically measured through returned pill counts, patient diary records of doses taken, and/or pharmacokinetic sampling to confirm drug exposure, as specified in the protocol.
Question 4: If a site's pharmacy refrigerator storing investigational product fails overnight, the CRA should advise the site to:
- Immediately discard all affected IP without notifying the sponsor
- Document the excursion details (temperature range, duration) and contact the sponsor's clinical supply team for disposition guidance before dispensing affected product (Correct answer)
- Continue dispensing the product since one night is unlikely to matter
- Replace the IP from their own supply
Correct answer: Document the excursion details (temperature range, duration) and contact the sponsor's clinical supply team for disposition guidance before dispensing affected product
Temperature excursions must be fully documented and assessed by the sponsor's supply and quality teams before any affected product is used; dispensing compromised IP could harm subjects.
Question 5: An IP 'expiry date extension' means:
- The protocol enrollment period has been extended
- The sponsor has performed additional stability testing and obtained regulatory approval to extend the product's use-by date (Correct answer)
- The site can continue using expired IP if no new supplies are available
- The IRB has approved additional drug use beyond the original period
Correct answer: The sponsor has performed additional stability testing and obtained regulatory approval to extend the product's use-by date
Expiry extensions require new stability data demonstrating the product remains within specifications, followed by updated labeling and regulatory notification where required.
Question 6: What is the purpose of a 'double-blind dummy' (matching placebo or active control) in a clinical trial?
- To reduce manufacturing costs
- To maintain blinding by ensuring all treatment arms have identical appearance, so neither subjects nor site staff can distinguish active from placebo (Correct answer)
- To provide a backup supply of investigational product
- To satisfy FDA labeling requirements
Correct answer: To maintain blinding by ensuring all treatment arms have identical appearance, so neither subjects nor site staff can distinguish active from placebo
Matching placebos or dummy controls are formulated to be identical in appearance, taste, and texture to the active product, preserving blinding integrity throughout the trial.
CCRA Investigational Product Management 2
Good Manufacturing Practice (GMP) requirements for investigational products are primarily intended to ensure: